Valuation: Zai Lab Limited

Market Cap 292Cr 250.13Cr 234.04Cr 214.24Cr 402.06Cr 28TCr 407.38Cr 2.77TCr 1.08TCr 14TCr 1.1TCr 1.07TCr 46TCr P/E 2026 *
-11.5x
P/E 2027 * -12.1x
Enterprise Value 246.24Cr 210.93Cr 197.36Cr 180.66Cr 339.05Cr 24TCr 343.53Cr 2.33TCr 909.31Cr 12TCr 924.6Cr 904.49Cr 39TCr EV / Sales 2026 *
5.83x
EV / Sales 2027 * 4.46x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 week+0.89%
Current month+43.95%
1 month+25.56%
3 months+39.51%
6 months+33.73%
Current year+51.68%
1 week 21.6
Extreme 21.6
23
1 month 15.4
Extreme 15.4
23
3 years 12.8
Extreme 12.8
38.8
5 years 12.8
Extreme 12.8
128
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.89%-23.13%+2.73% 292Cr
+0.90%+3.80%+41.49%-0.78% 8.33TCr
+8.86%+129.20%+435.14%+24.85% 5.79TCr
-1.69%+23.30%-22.30%-36.29% 5.78TCr
-1.46%+0.19%-2.06%+30.50% 5.17TCr
+1.74%+4.43%+12.37%+169.64% 4.93TCr
+1.13%+3.31%+55.61%-17.57% 3.2TCr
+0.46%+6.37%+50.29%+97.27% 2.59TCr
+1.19%+9.17%+2.97%+230.86% 2.27TCr
-0.30%+4.45%+58.29%+118.84% 1.69TCr
Average +1.20%+20.47%+60.87%+62.00% 4.42TCr
Weighted average by Cap. +1.44%+24.97%+79.74%+46.05%

Financials

2026 *2027 *
Net sales 42Cr 36Cr 34Cr 31Cr 58Cr 4.04TCr 59Cr 400.22Cr 156.07Cr 2.03TCr 158.7Cr 155.24Cr 6.72TCr 57Cr 49Cr 46Cr 42Cr 78Cr 5.44TCr 79Cr 538.7Cr 210.08Cr 2.73TCr 213.61Cr 208.96Cr 9.04TCr
Net income -25Cr -21Cr -20Cr -18Cr -34Cr -2.34TCr -34Cr -232.05Cr -90Cr -1.18TCr -92Cr -90Cr -3.9TCr -19Cr -16Cr -15Cr -14Cr -26Cr -1.79TCr -26Cr -177Cr -69Cr -898.37Cr -70Cr -69Cr -2.97TCr
Net Debt -46Cr -39Cr -37Cr -34Cr -63Cr -4.38TCr -64Cr -433.37Cr -169Cr -2.2TCr -171.84Cr -168.11Cr -7.28TCr -38Cr -33Cr -31Cr -28Cr -52Cr -3.64TCr -53Cr -360.61Cr -140.63Cr -1.83TCr -142.99Cr -139.88Cr -6.05TCr
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
21/26/21 €22.60 0.00%
20/26/20 €22.60 -1.74%
19/26/19 €23.00 +3.60%
18/26/18 €22.20 0.00%
17/26/17 €22.20 -0.89%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
26.01USD
Average target price
32.39USD
Spread / Average Target
+24.53%

Quarterly revenue - Rate of surprise